InnoStar is proud to present our Ophthalmology Integrated Evaluation Platform- a GLP-certified, end-to-end solution for ophthalmic drug development. Integrating toxicology, pharmacodynamics, pathology, ophthalmology, molecular biology, and pharmacokinetics, we provide comprehensive "efficacy-PK-toxicity" assessments that meet FDA, OECD, and international regulatory standards.

Our platform supports a wide spectrum of ocular disease models and advanced drug delivery techniques, enabling robust preclinical evaluation for gene therapies, oligonucleotides, biologics, small molecules, and cell-based treatments.

Key Capabilities Include:

• Broad Disease Models: Wet AMD, diabetic retinopathy, dry eye, glaucoma, cataract, myopia, uveitis, and more
• Advanced Administration Routes: Intravitreal, subretinal, suprachoroidal, anterior chamber, and subconjunctival injections
• Cross-Species Translational Expertise: From rodents to non-human primates
• Comprehensive Ophthalmic Diagnostics: Histopathology, IHC, tissue sampling, and biomarker analysis
• Regulatory-Grade Data: Supporting IND submissions in China, U.S., Europe, and Australia

With a proven track record-including IND clearances for gene therapies like NFS-02 (LHON) and NFS-05 (ADOA)-InnoStar delivers reliable, data-driven insights to de-risk and accelerate your ophthalmic R&D.